Piramal Pharma Limited (IN:PPLPHARMA)
:PPLPHARMA
PPLPHARMA Stock Chart & Stats
₹192.65
-₹4.80(-1.92%)
At close: 4:00 PM EST
₹192.65
-₹4.80(-1.92%)
Day’s Range― - ―
52-Week Range₹132.50 - ₹241.00
Previous CloseN/A
Volume1.66M
Average Volume (3M)264.14K
Market Cap
₹188.82B
Enterprise Value₹231.45B
Total Cash (Recent Filing)₹7.44B
Total Debt (Recent Filing)₹48.51B
Price to Earnings (P/E)―
Beta0.81
Next Earnings
May 27, 2026EPS Estimate
0.84Next Dividend Ex-DateN/A
Dividend Yield0.08%
Share Statistics
EPS (TTM)-0.70
Shares Outstanding1,329,248,200
10 Day Avg. Volume501,791
30 Day Avg. Volume264,138
Financial Highlights & Ratios
PEG Ratio0.84
Price to Book (P/B)3.72
Price to Sales (P/S)3.34
P/FCF Ratio132.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.28
Revenue Forecast (FY)₹102.34B
Bulls Say, Bears Say
Bulls Say
High Gross MarginA ~64.7% gross margin is a durable structural strength, indicating strong pricing power or low direct production costs in CDMO and specialty segments. High gross margins create ongoing room to cover SG&A, fund R&D/capacity expansion, and absorb pricing pressure over the next 2–6 months.
Manageable LeverageA debt-to-equity near 0.6 signals a balanced capital structure that reduces refinancing risk and preserves financial flexibility. This allows the company to support capex, working capital needs, or selective acquisitions without excessive strain on cash flow in the medium term.
Diversified Business Mix (CDMO + Specialty)A two-pronged model—contract development/manufacturing plus specialty product sales—provides durable revenue diversification. CDMO projects offer multi-year contracts and recurring manufacturing volumes, while specialty products give branded revenue streams, lowering single-channel exposure.
Bears Say
Inconsistent Net MarginsVolatile net margins imply earnings are sensitive to project mix, one-offs, or variable SG&A and R&D timing. That unpredictability weakens earnings quality and complicates capital allocation, making sustainable profit improvement uncertain over the next several quarters.
Volatile Free Cash FlowSignificant swings in free cash flow reduce the company's ability to consistently fund growth initiatives, pay down debt, or return capital. Fluctuating FCF suggests capex timing or working-capital variability that could constrain strategic investments over the medium term.
Sharp EPS DeclineA very large negative EPS growth rate reflects acute profitability deterioration or one-off charges that materially eroded earnings. Such a sharp EPS decline indicates underlying earnings fragility and raises questions about sustainable net income generation in coming quarters.
Piramal Pharma Limited News
PPLPHARMA FAQ
What was Piramal Pharma Limited’s price range in the past 12 months?
Piramal Pharma Limited lowest stock price was ₹132.50 and its highest was ₹241.00 in the past 12 months.
What is Piramal Pharma Limited’s market cap?
Piramal Pharma Limited’s market cap is ₹188.82B.
When is Piramal Pharma Limited’s upcoming earnings report date?
Piramal Pharma Limited’s upcoming earnings report date is May 27, 2026 which is in 54 days.
How were Piramal Pharma Limited’s earnings last quarter?
Piramal Pharma Limited released its earnings results on Jan 28, 2026. The company reported -₹0.7 earnings per share for the quarter, missing the consensus estimate of -₹0.245 by -₹0.455.
Is Piramal Pharma Limited overvalued?
According to Wall Street analysts Piramal Pharma Limited’s price is currently Overvalued.
Does Piramal Pharma Limited pay dividends?
Piramal Pharma Limited pays a Notavailable dividend of ₹0.14 which represents an annual dividend yield of 0.08%. See more information on Piramal Pharma Limited dividends here
What is Piramal Pharma Limited’s EPS estimate?
Piramal Pharma Limited’s EPS estimate is 0.84.
How many shares outstanding does Piramal Pharma Limited have?
Piramal Pharma Limited has 1,329,248,200 shares outstanding.
What happened to Piramal Pharma Limited’s price movement after its last earnings report?
Piramal Pharma Limited reported an EPS of -₹0.7 in its last earnings report, missing expectations of -₹0.245. Following the earnings report the stock price went up 1.015%.
Which hedge fund is a major shareholder of Piramal Pharma Limited?
Currently, no hedge funds are holding shares in IN:PPLPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company. It sells a portfolio of pharma products, as well as provides various pharma services, including injection, HPAPI, etc. The company was incorporated in 2020 and is based in Mumbai, India. Piramal Pharma Limited operates as a subsidiary of Piramal Enterprises Limited.
Technical Analysis
AstraZeneca Pharma India Limited
―
Gland Pharma Ltd.
―
IPCA Laboratories Limited
―
JB Chemicals & Pharmaceuticals Ltd.
―
PFIZER LIMITED
―